The Irritable Bowel Syndrome Treatment Market Size was valued at USD 3.05 Billion in 2023 and is expected to reach USD 6.46 Billion by 2032 and grow at a CAGR of 8.7% over the forecast period 2024-2032. This report puts emphasis on the rising incidence and prevalence of IBS, fueled by changing lifestyles, stress levels, and food habits, besides reviewing regional IBS drug prescription trends, including regional differences in treatment preferences and access. The report also reviews healthcare expenditure on the treatment of IBS in government, commercial, private, and out-of-pocket segments, delineating the economic burden of the disease. The report also examines developing therapeutic trends, including the growth in gut microbiome-targeted treatments and targeted therapeutics, as well as increasing impact of lifestyle and dietary trends on market demand, highlighting the move towards holistic and non-pharmacological management of IBS.
Get more information on Irritable Bowel Syndrome Treatment Market - Request Sample Report
Market Dynamics
Drivers
The IBS treatment market is driven by rising prevalence of irritable bowel syndrome (IBS) globally.
IBS treatment is driven by escalating prevalence of irritable bowel syndrome (IBS) worldwide, with research supporting that 10-15% of the worldwide population has IBS, while only 40% receive medical treatment. More awareness and rate of diagnosis increased the demand for specialized treatments such as Linzess (Linaclotide), Xifaxan (Rifaximin), and Viberzi (Eluxadoline). Furthermore, improvements in drug discovery, such as microbiome-specific therapies and gut-targeted neuromodulators, are increasing treatment effectiveness and patient outcomes. The transition towards personalized medicine and non-invasive diagnostics is also fueling market growth. Furthermore, growing incorporation of dietary and probiotic-based strategies, including the low FODMAP diet and therapy with gut microbiota, is complementing conventional pharmacological therapy. Pharmaceutical firms are aggressively investing in R&D, with Ironwood Pharmaceuticals, Takeda, and Ardelyx driving innovation. In addition, positive reimbursement policies in established markets have enhanced access to new therapies. Increasing demand for over-the-counter (OTC) medications and self-care products, especially in retail pharmacies, is also driving the market. The development of digital healthcare solutions and symptom monitoring using AI is another major driver, enhancing the management of diseases and patient compliance with treatment protocols.
Restraints
The high cost of advanced IBS medications and limited insurance coverage in certain regions.
Several new drugs, including Linzess and Viberzi, are costly, which impairs access, particularly in low- and middle-income nations. Moreover, side effects that arise from drugs used in the treatment of IBS, including diarrhea, bloating, and abdominal pain, result in patient nonadherence and drug discontinuation. Linzess (Linaclotide), for instance, can effectively manage IBS-C but tends to induce diarrhea, making patients reluctant to continue treatment. Another major challenge is the absence of a clear diagnostic test for IBS, with consequent underdiagnosis and misdiagnosis. IBS symptoms are confusingly similar to other gastrointestinal illnesses such as Inflammatory Bowel Disease (IBD) and Celiac Disease, making them difficult to accurately diagnose. Finally, social stigma associated with IBS discourages many patients from visiting doctors. Regulatory hurdles are also a hindrance, in that strict approval procedures for novel IBS therapies can slow the entry of drugs into the marketplace. For example, Synthetic Biologics' SYN-010, a treatment for IBS-C that is still in the investigative stage, has been delayed because of prolonged clinical trial phases. Lastly, the absence of curative drugs implies that existing drugs are only aimed at alleviating symptoms and not at treating the root cause, thus constraining long-term treatment efficacy.
Opportunities
The rising adoption of microbiome-based therapies and personalized medicine.
Growth in gut microbiota- targeted treatments, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), provides viable alternatives to conventional drug treatments. Biologic and small-molecule drugs are growing investments for companies, with Ardelyx's Ibsrela (Tenapanor) emerging as a new treatment option for IBS-C. Digital health solutions also represent a huge opportunity, such as AI-based symptom tracking applications and telemedicine platforms, improving patient engagement and treatment compliance. Retail pharmacy development also holds promise, with more and more patients seeking OTC therapy, dietary supplements, and lifestyle-based treatments to control symptoms. Further, widening clinical research into the genetic and neurobiologic underpinnings of IBS may bring about paradigm-breaking therapies aimed at the gut-brain axis. Furthermore, government programs and investments in gastrointestinal research are fueling the creation of new therapies. Strategic acquisitions and collaborations among leading pharmaceutical firms, like Ironwood and AbbVie's collaboration for Linzess, further provide channels for innovation and market expansion.
Challenges
The IBS treatment market faces several challenges, primarily due to the complex nature of IBS diagnosis and treatment.
One of the biggest challenges is the high level of patient variability in response to current treatments, which complicates standardization of therapy. For instance, while Linzess (Linaclotide) is effective in some IBS-C patients, others have profound diarrhea and discomfort, causing them to discontinue. Another major challenge is the lengthy development period for new IBS medications since clinical trials demand large amounts of patient data and regulatory approvals, which slows market entry. For example, Synthetic Biologics' SYN-010 has encountered prolonged trial durations as a result of difficulties in demonstrating its effectiveness. Moreover, the psychological aspect of IBS, which is commonly associated with stress and anxiety, makes treatment challenging, necessitating a multidisciplinary strategy involving pharmacological and psychological interventions. Low awareness and misdiagnosis rates are still a significant issue, as a large number of IBS cases remain undiagnosed as a result of symptom overlap with other gastrointestinal diseases. In addition, herbal and alternative therapies like peppermint oil and curcumin supplements are becoming increasingly popular, competing with conventional pharmaceuticals. Finally, concerns over data privacy in digital health solutions for IBS management, including AI-based symptom tracking and telemedicine platforms, can hinder adoption through regulatory limitations and patient reluctance.
By Type
The IBS-D (Diarrhea-Predominant IBS) segment led the market in 2023 with the highest revenue share of 43.8%. The widespread prevalence of IBS-D, combined with the presence of targeted therapies like rifaximin (Xifaxan) and eluxadoline (Viberzi), has fueled its market leadership. Growing awareness, diagnosis rates, and strong physician preference for prescription drugs have fueled this dominance.
The IBS-C (Constipation-Predominant IBS) segment is expected to have the highest growth rate during the forecast period. The increasing uptake of Linzess (Linaclotide) and Amitiza (Lubiprostone), combined with rising patient awareness of available management options for IBS-C, is driving the growth of this segment. Further, the increase in patients visiting healthcare providers for chronic constipation symptoms has created a greater demand for prescription drugs.
By Drug Class
Linzess/Constella (Linaclotide) was the market leader in IBS treatment in 2023, with the highest revenue share of 32.3%. Its leadership is supported by its excellent efficacy in IBS-C treatment, extensive physician preference, and supportive reimbursement policies in major markets such as the U.S. and Europe. Its established status as a first-line treatment for IBS-C further reinforced its leadership in the market.
Viberzi (Eluxadoline) is expected to have the fastest growth in the coming years. Its rising usage for the treatment of IBS-D, driven by its two-mechanism approach acting on opioid receptors in the intestine, has boosted demand. The rising demand for targeted therapies compared to conventional anti-diarrheal drugs is also likely to propel its market growth.
By Distribution Channel
Hospital pharmacies dominated the IBS treatment market in 2023, accounting for the largest revenue share of 45.2%. Hospital sales were higher due to growing hospital visits for IBS conditions, a preference for specialist prescriptions, and the instantaneous availability of recommended medications for chronic IBS cases.
Retail pharmacies should see the strongest growth among treatment of IBS. Increased patient demand for over-the-counter (OTC) products and simplicity of accessing prescription drugs have grown sales via the retail route. The move toward direct purchases by consumers and wider pharmacist consulting services is driving segment growth even more.
Regional Analysis
North America led the IBS treatment market in 2023, with 34.2% revenue share owing to the widespread prevalence of IBS, robust healthcare infrastructure, and growing awareness regarding available treatments. The presence of major pharmaceutical firms, high prescription drug use such as Linzess and Xifaxan, and supportive reimbursement policies have also driven the market. The U.S. is at the forefront of the region with the highest diagnosis rates and growing demand for new therapies.
Europe has a strong market share, fueled by growing IBS incidence, growing healthcare spending, and government backing for IBS research. Germany, the UK, and France are among the countries that make a strong contribution to market growth because of improved access to sophisticated treatment methods. The use of microbiome-based treatments and dietary management strategies is also picking up in the region.
Asia-Pacific is predicted to observe the fastest growth, led by rising awareness, enhanced accessibility of healthcare, and investments in treatment of digestive health. China, Japan, and India are seeing heightened cases of IBS because of lifestyle changes, urbanization, and eating habits. Market growth is being driven by heightened availability of over-the-counter and prescription drugs as well as retail pharmacy network expansion.
Ironwood Pharmaceuticals, Inc. – Linzess (Linaclotide)
Allergan – Viberzi (Eluxadoline), Linzess (Co-marketed with Ironwood)
Astellas Pharma, Inc.
Takeda Pharmaceutical Company Limited – Amitiza (Lubiprostone)
AstraZeneca
Sanofi S.A.
Sebela Pharmaceuticals Inc. – Motofen (Difenoxin/Atropine)
Bausch Health – Xifaxan (Rifaximin)
Synthetic Biologics, Inc. – SYN-010 (Investigational therapy for IBS-C)
Ardelyx – Ibsrela (Tenapanor)
Recent Developments
In Feb 2025, Michigan Medicine and Cleveland Clinic researchers developed a new IBS treatment approach using a personalized diet based on blood test panels to eliminate trigger foods. Conducted across eight research centers, the study aims to alleviate IBS symptoms and improve patient quality of life.
In Feb 2025, Sanofi and Teva Pharmaceuticals unveiled new detailed data from the RELIEVE UCCD Phase 2b study on duvakitug (TEV’574/SAR447189), demonstrating its efficacy in treating moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). The findings reinforce its potential as a novel therapy for inflammatory bowel disease (IBD).
In Dec 2024, Takeda Canada Inc. launched the MILESTONE Canada Advanced IBD Fellowship Initiative, aiming to standardize training, build professional networks, and implement Entrustable Professional Activities (EPAs) for advanced Inflammatory Bowel Disease (IBD) fellows in Canada. This initiative reflects Takeda’s commitment to advancing IBD education and specialized care.
| Report Attributes | Details |
| Market Size in 2023 | USD 3.05 billion |
| Market Size by 2032 | USD 6.46 billion |
| CAGR | CAGR of 8.7% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type [IBS-Cs, IBS-D] • By Drug Class [Xifaxan, Linzess/Constella, Viberzi, Amitiza, Others] • By Distribution Channel [Hospital Pharmacy, Retail Pharmacy, Others] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sanofi S.A., Sebela Pharmaceuticals Inc., Bausch Health, Synthetic Biologics, Inc., Ardelyx. |
Irritable Bowel Syndrome Treatment market is expected to grow at a CAGR of 8.7% over the forecast period 2024-2032.
Government regulations that are extremely strict, and Patients are dissatisfied with the IBS treatment they are receiving are the restraints of the Irritable Bowel Syndrome Treatment.
Irritable Bowel Syndrome Treatment Market is divided into three segments and they are By Type, By Drug class, By distribution channel
North America led the IBS treatment market in 2023, with 34.2% revenue share owing to the widespread prevalence of IBS, robust healthcare infrastructure, and growing awareness regarding available treatments.
The IBS-D (Diarrhea-Predominant IBS) segment led the market in 2023 with the highest revenue share of 43.8%.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of IBS (2023)
5.2 Prescription Trends for IBS Medications (2023), by Region
5.3 Healthcare Spending on IBS Treatment, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
5.4 Emerging Therapeutic Trends in IBS Treatment
5.5 Impact of Lifestyle and Diet Trends on IBS Treatment Market
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Irritable Bowel Syndrome Treatment Market Segmentation, by Type
7.1 Chapter Overview
7.2 IBS-Cs
7.2.1 IBS-Cs Market Trends Analysis (2020-2032)
7.2.2 IBS-Cs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 IBS-D
7.3.1 IBS-D Market Trends Analysis (2020-2032)
7.3.2 IBS-D Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Irritable Bowel Syndrome Treatment Market Segmentation, by Drug Class
8.1 Chapter Overview
8.2 Xifaxan
8.2.1 Xifaxan Market Trends Analysis (2020-2032)
8.2.2 Xifaxan Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Linzess/Constella
8.3.1 Linzess/Constella Market Trends Analysis (2020-2032)
8.3.2 Linzess/Constella Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Viberzi
8.4.1 Viberzi Market Trends Analysis (2020-2032)
8.4.2 Viberzi Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Amitiza
8.5.1 Amitiza Market Trends Analysis (2020-2032)
8.5.2 Amitiza Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Others
8.6.1 Others Market Trends Analysis (2020-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Irritable Bowel Syndrome Treatment Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacy
9.2.1 Hospital Pharmacy Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacy
9.3.1 Retail Pharmacy Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.4 North America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.5 North America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.6.2 USA Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.6.3 USA Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.7.2 Canada Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.7.3 Canada Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.8.2 Mexico Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.8.3 Mexico Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.6.3 Poland Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.7.3 Romania Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.9 turkey
10.3.1.9.1 Turkey Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.5 Western Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.6.3 Germany Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.7.2 France Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.7.3 France Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.8.2 UK Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.8.3 UK Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.9.3 Italy Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.10.3 Spain Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.13.3 Austria Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.5 Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.6.2 China Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.6.3 China Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.7.2 India Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.7.3 India Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.8.2 Japan Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.8.3 Japan Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.9.2 South Korea Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.9.3 South Korea Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.10.3 Vietnam Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.11.2 Singapore Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.11.3 Singapore Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.12.2 Australia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.12.3 Australia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.4 Middle East Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.5 Middle East Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.6.3 UAE Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.4 Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.5 Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.4 Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.5 Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.6.2 Brazil Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.6.3 Brazil Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.7.2 Argentina Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.7.3 Argentina Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.8.2 Colombia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.8.3 Colombia Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 Ironwood Pharmaceuticals, Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 Allergan
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Astellas Pharma, Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Takeda Pharmaceutical Company Limited
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 AstraZeneca
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 Sanofi S.A.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Sebela Pharmaceuticals Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 Bausch Health
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 Synthetic Biologics, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Ardelyx
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Type
IBS-Cs
IBS-D
By Drug Class
Xifaxan
Linzess/Constella
Viberzi
Amitiza
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Prefilled Syringes Market was valued at USD 7.31 billion in 2023 and is expected to reach USD 21.30 billion by 2032, growing at a CAGR of 12.51% from 2024 to 2032.
The Electronic Clinical Outcome Assessment Solutions Market was valued at USD 1.57 billion in 2023 and is expected to reach USD 5.64 billion by 2032, growing at a CAGR of 15.3% over the forecast period of 2024-2032.
Medical Image Management Market was valued at USD 4.88 billion in 2023 and is expected to reach USD 9.06 billion by 2032, growing at a CAGR of 7.18% from 2024-2032.
The Peptic Ulcer Drugs Market size was USD 4.87 Billion in 2023 and is expected to reach USD 6.43 Billion by 2032 and grow at a CAGR of 3.16% over the forecast period of 2024-2032.
The Elderly Walker Market was valued at USD 1.56 billion in 2023 and is expected to reach USD 2.73 billion by 2032, growing at a CAGR of 6.44% from 2024 to 2032
The Dyspnea Treatment Market Size was valued at USD 6.16 Billion in 2023 and is expected to reach USD 11.01 Billion by 2032 and grow at a CAGR of 6.95% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
